National Oncology Institute
- Address
- Klenova 1, 833 10 Bratislava, Slovakia
National Oncology Institute - Advanced Cancer Research Center
The National Oncology Institute stands at the forefront of innovative cancer therapeutics, conducting pivotal Phase 2 and Phase 3 clinical trials across a diverse spectrum of malignancies. The center demonstrates exceptional expertise in precision medicine approaches, particularly in BRAF-mutated cancers and hematologic malignancies, while advancing novel combination therapies that integrate targeted agents, immunotherapy, and chemotherapy regimens.
- Melanoma and Colorectal Cancer: Pioneering BRAF V600E/K-targeted therapy combinations with immune checkpoint inhibitors
- Hematologic Malignancies: Advanced trials in chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma utilizing BTK inhibitors and bispecific antibodies
- Breast Cancer Research: Novel antibody-drug conjugates and CDK4/6 inhibitor studies in triple-negative and hormone receptor-positive disease
- Prostate Cancer: Investigating CDK4 inhibitors in combination with hormonal therapies for metastatic castration-resistant disease
The Institute's research portfolio emphasizes biomarker-driven patient selection and innovative drug combinations designed to overcome resistance mechanisms. With expertise spanning solid tumors and blood cancers, the center actively enrolls patients in registration-enabling studies evaluating next-generation targeted therapies, bispecific T-cell engagers, and combination immunotherapy approaches that represent the future of precision oncology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 43 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 43 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Ascentage Pharma Group Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.4trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in National Oncology Institute
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) [frontMIND] | Incyte Corp. | Phase III | Not Recruiting | Apr 2021 | — |
IMP list
lock Showing 1 of 43 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Encorafenib | 3 | Unknown | 2021-02-16 | 2023-05-24 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.